Page 11 - Clin Cardiol News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Clin cardiol. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Clin Cardiol Today - Breaking & Trending Today

REDUCE-IT® Heart Failure Analyses by VASCEPA® (Icosapent Ethyl)-Driven Serum Eicosapentaenoic Acid (EPA) Levels Suggest Potential Benefit in New Heart Failure in Studied At-Risk Patients as Presented at the American College of Cardiology's 70th Annual Scientific Session


Share:
Post hoc analyses by estimated on-treatment serum EPA levels in the VASCEPA group suggest potentially reduced incidence of new heart failure and new heart failure requiring hospitalization with higher achieved serum EPA levels
Amarin to Webcast Discussion of Data Presented at ACC.21 Monday, May 17, 2021 at 4:30 p.m., Eastern Time
DUBLIN, Ireland and BRIDGEWATER, N.J., May 15, 2021 (GLOBE NEWSWIRE) Amarin Corporation plc (NASDAQ:AMRN) today announced the presentation of REDUCE-IT
® HEART FAILURE (HF) at ACC.21, the American College of Cardiology s 70th Annual Scientific Session, being held virtually from May 15 – 17, 2021. These new analyses supported by Amarin were presented on behalf of all authors by Deepak L. Bhatt, M.D., M.P.H., Brigham and Women s Hospital, Harvard Medical School, Boston, MA. ....

United States , New Jersey , United Arab Emirates , Clin Cardiol , Coll Cardiol , Craig Granowitz , Steven Ketchum , Deepakl Bhatt , American Heart Association , American College Of Cardiology , Drug Administration , Vascular Center , Harvard Medical School , Professor Of Medicine At Harvard Medical School , Exchange Commission , Amarin Corporation , Journal Of The American College Cardiology , European Union , Amarin Pharmaceuticals Ireland , A Report From The American Heart Association , Webcast Discussion , Data Presented , American College , Annual Scientific Session , Executive Director , Interventional Cardiovascular Programs ,

Amarin Reports First Quarter 2021 Financial Results and Provides Business Update


Share:
Commercial Launch of VAZKEPA in Europe on Track to Commence in Q3 2021 Following Recent Market Authorization with VASCEPA® Growth in the United States Positioned to Increase as the Impact of COVID-19 Recedes
Expenses Managed in Q1 2021 to Minimize Operating Loss Despite Revenue Impact of COVID-19 and Other Factors
Management to Host Conference Call Today at 7:30 a.m. ET
DUBLIN, Ireland and BRIDGEWATER, N.J., April 29, 2021 (GLOBE NEWSWIRE) Amarin Corporation plc (NASDAQ:AMRN), today announced financial results for the quarter ended March 31, 2021 and provided an update on company operations.
Recent Key Amarin Highlights:
Q1 net total revenue
: Net total revenue in the first quarter of 2021 was $142.2 million, consisting of $140.8 million in net product revenue from the United States, $0.5 million in net product revenue from outside the United States and $0.8 million in licensing and royalty revenue. Net product revenue from the United State ....

United States , Hong Kong , New Jersey , United Kingdom , United Arab Emirates , Northern Ireland , Great Britain , Coll Cardiol , Clin Cardiol , Karim Mikhail , John Thero , Joseph Kennedy , American Heart Association , Exchange Commission Regulation , European Society Of Cardiology , Journal Of The American College Cardiology , Amarin Pharmaceuticals Ireland , European Union , Chinese National Medical Products Administration , Symphony Health , Drug Administration , European Commission , Exchange Commission , Hong Kong Department Of Health , Amarin Corporation , Chinese Society Of Cardiology ,